Hormone Therapy & GLP-1 Medications: What New Research Means After Menopause
Many women tell us that managing their weight becomes more difficult during the menopause transition. Their usual routines may no longer produce the same results, and changes around the waist can feel especially frustrating.
These concerns deserve an individualized assessment. In our practice, we consider menopause symptoms, sleep, nutrition, muscle health, activity, and metabolic factors together when helping women develop a treatment plan.
GLP-1 medications have expanded the options available for weight management. Now, researchers are asking whether menopause hormone therapy might influence how women respond to these treatments.
Early studies suggest that women using hormone therapy may lose more weight with semaglutide than women who are not. The research is encouraging, but it also calls for careful interpretation.
Understanding the Midlife Picture
Menopause symptoms and weight concerns often occur at the same time, but they do not necessarily have the same cause or require the same treatment.
A woman may be dealing with disrupted sleep, hot flashes, changes in activity, or difficulty maintaining consistent meals and exercise. Her medical history and current medications may also affect the choices available to her.
That is why we take time to understand the full picture. We want to know what has changed, what you have already tried, how you are feeling, and which outcomes matter most to you.
The emerging research on hormone therapy and GLP-1 medications adds another consideration to that conversation. It may eventually help clarify how to personalize treatment more effectively, but it does not replace an individual evaluation.
What the First Study Found
A study published in Menopause in 2024 reviewed the medical records of 106 postmenopausal women with overweight or obesity who were taking semaglutide, the active ingredient in Wegovy and Ozempic. Sixteen women were also using menopause hormone therapy, while 90 were not.
Women using hormone therapy lost more weight at the measured follow-up points. At 12 months, their average weight loss was approximately 16% of starting body weight, compared with 12% among women not using hormone therapy. The association remained after researchers adjusted for several factors that could affect weight loss. [1]
For clinicians and patients, this raises an important question: could treating menopausal symptoms and managing weight together influence treatment outcomes?
What the Larger Study Adds
A larger retrospective study presented at The Menopause Society’s October 2026 annual meeting examined records from nearly 2,400 women receiving semaglutide and nearly 1,500 receiving tirzepatide, the active ingredient in Mounjaro and Zepbound.
Among semaglutide users, hormone therapy was associated with greater weight loss that persisted over time. Among tirzepatide users, an early difference was observed, but the difference was no longer statistically significant at the end of the study. [2]
The larger number of participants makes this research useful, but it remains observational. Conference findings also require further scrutiny through full publication and peer review. Randomized trials would help determine whether hormone therapy itself contributes to the additional weight loss and which women, if any, are most likely to benefit. [2]
Does This Mean You Need Hormone Therapy?
No. These findings do not mean women need hormone therapy to benefit from GLP-1 treatment, and weight loss alone is not an indication for menopause hormone therapy. [2]
We assess the reasons for each treatment separately. If you have menopausal symptoms, we discuss whether hormone therapy is appropriate based on those symptoms, your medical history, and your individual benefits and risks and potential for disease prevention from the “Fatal Four”- dementia, heart disease, osteoporosis and diabesity. If you are considering weight management medication, we evaluate your eligibility, weight-related health concerns, treatment goals, and potential side effects.
For some women, both treatments may be appropriate. For others, one may be appropriate, or a different approach may better fit their needs.
The research gives us a reason to keep asking thoughtful questions. It does not create a universal prescription.
A Comprehensive Approach to Your Results
When we help a patient manage weight after menopause, our goals extend beyond weight loss. We also want to support strength, adequate nutrition, physical function, and a treatment plan she can sustain.
That means discussing protein intake, resistance exercise, sleep, daily activity, and how medication may affect appetite and eating patterns. Follow-up gives us an opportunity to review progress, address side effects, and adjust the plan when needed.
We also want to understand your experience. Are your symptoms improving? Are you eating adequately? Are you maintaining strength? Does the plan feel manageable? Those answers help us judge whether treatment is serving your broader health goals.
What This Means for You
The connection between menopause hormone therapy and GLP-1 treatment is an evolving area of research. Early findings suggest an association with greater weight loss, particularly with semaglutide, but important questions remain about cause, long-term outcomes, and who may benefit most.
Our approach is to bring new evidence into the conversation while keeping your individual needs at the center of care.
If you are experiencing menopause symptoms and changes in your weight, we would be happy to review your options with you. Together, we can develop a plan that addresses your concerns and supports your health through menopause and beyond.
To explore a personalized plan for menopause and weight management, schedule an appointment with renowned menopause expert Ruthie Harper, MD in Austin, TX.
Austin, TX GLP1 & HRT Doctor: 512-343-9355
.
Research Sources
[1] Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause (2024).
https://doi.org/10.1097/GME.0000000000002310
[2] Hormone Therapy May Increase Weight Loss Effectiveness of GLP-1s. The Menopause Society (2026 annual meeting findings; conference report).
https://menopause.org/press-releases/hormone-therapy-may-increase-weight-loss-effectiveness-of-glp-1s











